# Phenotypic reversion of fair hair upon gene therapy of the phenylketonuria mice

Thöny, Beat ; Ding, Zhaobing ; Rebuffat, Alexandre ; Viecelli, Hiu Man

DOI: https://doi.org/10.1089/hum.2014.029

HUMAN GENE THERAPY 25:573–574 (July 2014)

DOI: 10.1089/hum.2014.029



# Phenotypic Reversion of Fair Hair upon Gene Therapy of the Phenylketonuria Mice

Beat Thöny,[1] Zhaobing Ding,[1,*] Alexandre Rebuffat,[1] and Hiu Man Viecelli[1]




**FIG. 1.** Phenotypic reversion from brown to black coat color of treated phenylketonuria (PKU) (*Pah-enu2*) mouse (see text for details).

[1]Division of Metabolism, Department of Pediatrics, University of Zürich, CH-8032 Zürich, Switzerland.
**Current address:* Singapore Bioimaging Consortium (SBIC), Biomedical Sciences Institutes, Helios, Singapore 38667.

PHENYLKETONURIA (PKU) (OMIM261600) is an autosomal recessive genetic disorder characterized by accumulation of the essential amino acid L-phenylalanine (L-Phe) in the body caused by deficiency of the hepatic enzyme phenylalanine hydroxylase (PAH; EC 1.14.16.1). Owing to attenuated biosynthesis of melanin due to systemic elevated L-Phe, hypopigmentation is one of the visible phenotypes of PKU. Such a phenotype can also be observed in PKU mice bearing the homozygous *Pah-enu2* allele, where it was reported that restoration of hypopigmentation needs at least 5% of the PAH enzyme activity (Fang *et al*., 1994; Nagasaki *et al*., 1999; Viecelli *et al*., 2014). This phenotype was reversed in black 6 (C57Bl/6) PKU mice to wild-type level after hydrodynamic tail vein injection of a recombinant nonviral minicircle-based naked DNA vector expressing the murine *Pah*-cDNA from a liver-specific promoter. Young adult C57Bl/6 untreated wild-type and PKU mice carrying homozygously the *Pah-enu2* allele are shown in Figure 1 before (middle), and 6 weeks after infusion of the minicircle vector MC.PKU20 (Viecelli *et al.*, 2014). Fair-haired PKU mice started to darken after gene transfer and eventually became indistinguishable from wild-type. Changes from brown to black hair persisted from then on in minicircle vector–treated mice. Normalization of blood L-Phe concomitant with reversion of hypopigmentation in a dose-dependent manner can also be observed with other gene therapeutic vectors such as, for instance, after treatment of PKU with AAV2 serotype 8 (rAAV2/8-PKU5) to target liver or with rAAV2/1-mediated intramuscular expression of a complete L-Phe hydroxylating system (Ding *et al*., 2006, 2008).

## Acknowledgments

We thank the continuous support from the mass spectrometry units of the Divisions of Clinical Chemistry and Biochemistry and Newborn Screening, as well as Felix H. Sennhauser. Our work was supported by grants from the Children's Research Center Zurich, the Swiss National Science Foundation, the National Institutes of Health (Research Grant No. 1R01HD057033), and the Stiftung für wissenschaftliche Forschung der Universitat Zurich.

## References

Ding, Z., Georgiev, P., and Thöny, B. (2006). Administration-route and gender-independent long-term therapeutic correction of phenylketonuria (PKU) in a mouse model by recombinant adeno-associated virus 8 pseudotyped vector-mediated gene transfer. Gene Ther. 13, 587–593.

Ding, Z., Harding, C.O., Rebuffat, A., *et al.* (2008). Correction of murine PKU following AAV-mediated intramuscular expression of a complete phenylalanine hydroxylating system. Mol. Ther. 16, 673–681.

Fang, B., Eisensmith, R.C., Li, X.H., *et al.* (1994). Gene therapy for phenylketonuria: phenotypic correction in a genetically deficient mouse model by adenovirus-mediated hepatic gene transfer. Gene Ther. 1, 247–254.

Nagasaki, Y., Matsubara, Y., Takano, H., *et al.* (1999). Reversal of hypopigmentation in phenylketonuria mice by adenovirus-mediated gene transfer. Pediatr. Res. 45, 465–473.

Viecelli, H.M., Harbottle, R.P., Wong, S.P., *et al.* (2014). Treatment of phenylketonuria (PKU) using minicircle-based naked-DNA gene transfer to murine liver. Hepatology. [Epub ahead of print]; DOI: 10.1002/hep.27104.

Address correspondence to:
*Dr. Beat Thöny*
*Division of Metabolism*
*Department of Pediatrics*
*University of Zürich*
*Steinwiesstrasse 75*
*CH-8032 Zürich*
*Switzerland*

*E-mail:* beat.thony@kispi.uzh.ch

Received for publication March 24, 2014;
accepted after revision May 15, 2014.

Published online: June 16, 2014.